{"disease":{"id":"relapsed-or-refractory-classical-hodgkin-lymphoma","name":"relapsed or refractory classical hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03327571","title":"B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05140382","title":"AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05216835","title":"Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}